Literature DB >> 16465136

[Epidemiology of visceral mycoses in patients with leukemia and MDS - Analysis of the data in annual of pathological autopsy cases in Japan in 1989, 1993, 1997 and 2001].

Hikaru Kume1, Toshikazu Yamazaki, Michiko Abe, Hiroyuki Tanuma, Masahiko Okudaira, Isao Okayasu.   

Abstract

To study the changes of visceral mycoses in autopsy cases, data on visceral mycosis cases with leukemia and myelodysplastic syndrome (MDS) reported in the Annual of the Pathological Autopsy Cases in Japan in 1989, 1993, 1997 and 2001 were analyzed. The frequency rate of visceral mycoses with leukemia and MDS was 27.9% (435/1,557) in 1989, 23.0% (319/1,388) in 1993, 22.3% (246/1,105) in 1997 and 25.1% (260/ 1,037) in 2001, which was clearly higher than the rate of cases without leukemia and MDS: 3.4%, 2.7%, 3.5% and 3.7%, respectively. Furthermore, in comparing the rate of mycoses in recipients of stem cell transplantation with that of non-recipients, that of recipients was about 10% higher. The predominant causative agents were Candida and Aspergillus, at approximately the same rate (Candida 33.6%, Aspergillus 33.3%) as in 1989. However, Aspergillus increased conspicuously in 1993 (Candida 22.3% Aspergillus 44.5%), and continued to increase (Candida 22.8%, Aspergillus 50.8% in 1997; Candida 16.9%, Aspergillus 54.2% in 2001). In aspergillosis and zygomycosis, the lung and bronchi comprised the most commonly infected organs: 74.7% and 75.6% of the total cases, respectively. Among a total of 1,260 cases with mycotic infections in the four years studied, acute lymphatic leukemia and acute myeloid leukemia were the major diseases (35.5% and 33.5%, respectively) followed by MDS (29.0%). Given these facts, we emphasize that a greater interest in mycoses should be taken by clinicians, and immunocompromised patients should be protected from opportunistic invasive fungal infections, especially aspergillosis.

Entities:  

Mesh:

Year:  2006        PMID: 16465136     DOI: 10.3314/jjmm.47.15

Source DB:  PubMed          Journal:  Nihon Ishinkin Gakkai Zasshi        ISSN: 0916-4804


  4 in total

1.  Risk Factors and Clinical Characteristics of Patients with Ocular Candidiasis.

Authors:  Toru Sakamoto; Kenji Gotoh; Kenyu Hashimoto; Chiyoko Tanamachi; Hiroshi Watanabe
Journal:  J Fungi (Basel)       Date:  2022-05-11

2.  Efficacy and safety of intravenous itraconazole as empirical antifungal therapy for persistent fever in neutropenic patients with hematological malignancies in Japan.

Authors:  Kensuke Ohta; Saori Nishiki Kosaka; Yoshitaka Nakao; Takeo Kumura; Kiyomichi Hagihara; Erina Sakamoto; Shuichiro Okamoto; Asao Hirose; Yasutaka Aoyama; Ryousuke Yamamura; Yoshiki Hayashi; Yukari Umemoto; Yoshiki Terada; Yasunobu Takeoka; Takahiko Nakane; Hideo Koh; Masayuki Hino
Journal:  Int J Hematol       Date:  2009-05-19       Impact factor: 2.490

3.  Efficacy and safety of micafungin for the prophylaxis of invasive fungal infection during neutropenia in children and adolescents undergoing allogeneic hematopoietic SCT.

Authors:  H J Park; M Park; M Han; B H Nam; K N Koh; H J Im; J W Lee; N-G Chung; B Cho; H-K Kim; K H Yoo; H H Koo; H J Kang; H Y Shin; H S Ahn; Y T Lim; H Kook; C J Lyu; J O Hah; J E Park; Y J Lim; J J Seo
Journal:  Bone Marrow Transplant       Date:  2014-07-07       Impact factor: 5.483

4.  A multicenter phase 2 study of empirical low-dose liposomal amphotericin B in patients with refractory febrile neutropenia.

Authors:  Kotaro Miyao; Masashi Sawa; Mio Kurata; Ritsuro Suzuki; Reona Sakemura; Toshiyasu Sakai; Tomonori Kato; Satomi Sahashi; Natsuko Tsushita; Yukiyasu Ozawa; Motohiro Tsuzuki; Akio Kohno; Tatsuya Adachi; Keisuke Watanabe; Kaneyuki Ohbayashi; Yuichiro Inagaki; Yoshiko Atsuta; Nobuhiko Emi
Journal:  Int J Hematol       Date:  2016-09-30       Impact factor: 2.319

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.